Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer pulls sickle cell treatment Oxbryta
Pfizer pulls sickle cell drug oxbryta, raising safety concerns
Pfizer’s abrupt withdrawal of Oxbryta, a drug for sickle cell disease, has sent shockwaves through the medical community.
Pfizer's Withdrawal of SCD Drug Raises Questions
Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical studies.
Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling
Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options,
Pfizer to Withdraw Sickle Cell Drug Oxbryta Lots from World-Wide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population.
Pfizer to withdraw sickle cell treatment OXBRYTA from market
Pfizer has announced the withdrawal of all lots of OXBRYTA approved for treating sickle cell disease (SCD) from worldwide markets.
Pfizer issues global market withdrawal of sickle cell disease therapy Oxbryta
Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. | Pfizer will voluntarily pull its sickle cell disease drug Oxbryta from all markets worldwide,
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta. Pfizer said late on Wednesday it was pulling the drug from all markets due to risk of a painful complication and death.
Agios cut at Leerink on overhang from Pfizer’s Oxbryta withdrawal
Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle cell disease drug, Oxbryta. Read more here.
What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA
European regulators on Thursday also said that patients in the trials had higher rates of the pain crises that are hallmarks of sickle cell disease once they started on Oxbryta, also called voxelotor,
1d
Pfizer starts voluntary withdrawal of OXBRYTA, benefit does not outweigh risks
The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
STAT
3d
Sickle cell community scrambles to find safe plan after a drug is pulled from the market
After Pfizer withdrew its sickle cell drug from the market, patients with the condition and their doctors were left ...
4d
on MSN
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...
5d
Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
BioSpace
4d
Pfizer Takes Sickle Cell Drug Oxbryta Off Global Market, Cites Risk of Death
Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...
devdiscourse
3d
Today’s Health Roundup: Schizophrenia Breakthrough and Bird Flu Vaccination Pressures
This health news roundup covers significant advances and alerts, including the approval of Bristol Myers' new schizophrenia ...
Yahoo Finance
3d
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
Pfizer PFE said it is withdrawing its sickle-cell drug (“SCD”) drug,
Oxbryta
from worldwide markets. Merck’s MRK Keytruda ...
STAT
3d
Biotech’s real estate market is still upside down
Medicare’s controversial decision to condition coverage for even fully approved Alzheimer’s drugs is here to stay, per a top ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Pfizer
Sickle cell disease
Food and Drug Administration
Feedback